Published in Indian J Med Res on March 01, 1981
Dermatophyte lipids-Composition and regulation of phospholipids. Indian J Clin Biochem (2000) 0.75
The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell (1993) 7.71
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother (2003) 1.49
Geriatric assessment teams in nursing homes: do they work? J Am Osteopath Assoc (1993) 1.46
Incidental focal colonic lesions found on (18)Fluorodeoxyglucose positron emission tomography/computed tomography scan: further support for a national guideline on definitive management. Colorectal Dis (2012) 1.44
Mitral valve repair in a predominantly rheumatic population. Long-term results. Tex Heart Inst J (2001) 1.39
Agreement between head of household informant and self-report in a community survey of substance use in India. Drug Alcohol Depend (2003) 1.26
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) (2005) 1.25
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) (2003) 1.18
Cellular basis for the species differences in sensitivity to cardiac glycosides (digitalis). J Cell Physiol (1986) 1.15
Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J (2000) 1.15
Genetic and biochemical studies with mutants of mammalian cells affected in microtubule-related proteins other than tubulin: mitochondrial localization of a microtubule-related protein. Can J Biochem Cell Biol (1985) 1.14
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents (2005) 1.14
In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett (2005) 1.13
Reducing chimera formation during PCR amplification to ensure accurate genotyping. Gene (2010) 1.12
Myiasis due to tumbu fly. Lancet (1985) 1.12
Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother (2005) 1.11
Phospholipids of Clostridium butyricum. V. Effects of growth temperature on fatty acid, alk-1-enyl ether group, and phospholipid composition. J Lipid Res (1974) 1.09
Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett (2006) 1.09
Rheumatic-musculoskeletal pain and disorders in a naïve group of individuals 15 months following a Chikungunya viral epidemic in south India: a population based observational study. Int J Clin Pract (2011) 1.08
Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm (2005) 1.04
Signaling through protein kinases and transcriptional regulators in Candida albicans. Crit Rev Microbiol (2003) 1.02
Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Int J Antimicrob Agents (2006) 1.02
The human transcription enhancer factor-1, TEF-1, can substitute for Drosophila scalloped during wingblade development. J Biol Chem (1997) 1.02
Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother (2001) 1.01
Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother (2001) 1.01
The co-occurrence of tobacco & alcohol in general population of metropolis Delhi. Indian J Med Res (2002) 1.00
Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Int J Pharm (2002) 0.99
Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother (2004) 0.99
Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents (2001) 0.97
Further studies on the lipids of corynebacteria. The mannolipids of Corynebacterium aquaticum. Biochem J (1972) 0.96
Innate antiviral defenses in body fluids and tissues. Antiviral Res (2000) 0.96
Does buprenorphine maintenance improve the quality of life of opioid users? Indian J Med Res (2013) 0.95
Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol (2007) 0.95
Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents (2004) 0.94
Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother (1997) 0.94
Effects of growth temperature and supplementation with exogenous fatty acids on some physical properties of Clostridium butyricum phospholipids. Biochim Biophys Acta (1977) 0.94
A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect (2006) 0.94
Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis (2004) 0.93
Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb) (2005) 0.92
Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother (2006) 0.92
Biochemical interaction of human neutrophil peptide-1 with Mycobacterium tuberculosis H37Ra. Arch Microbiol (1999) 0.92
On the mannophosphoinositides of Mycobacterium 607. Experientia (1968) 0.92
Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 0.92
Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother (2003) 0.91
Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles. Int J Antimicrob Agents (2007) 0.91
Effect of camel milk on glycemic control and insulin requirement in patients with type 1 diabetes: 2-years randomized controlled trial. Eur J Clin Nutr (2011) 0.91
Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother (2004) 0.91
Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model. Protein Expr Purif (2006) 0.90
Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother (2004) 0.90
Incidence estimates of substance use disorders in a cohort from Delhi, India. Indian J Med Res (2002) 0.90
Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis. Infect Immun (2005) 0.90
Comparative evaluation of the diagnostic significance of circulating immune complexes and antibodies to phosphatidylinositomannosides in pulmonary tuberculosis by enzyme-linked immunosorbent assay. Med Microbiol Immunol (1989) 0.90
Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci (2008) 0.90
Lung and blood mononuclear cell responses of tuberculosis patients to mycobacterial proteins. Eur Respir J (2006) 0.89
DNA vaccines: future strategies and relevance to intracellular pathogens. Immunol Cell Biol (2001) 0.88
A rapid assessment study on prevalence of substance abuse disorders in metropolis Delhi. Indian J Med Res (2001) 0.88
Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine (2005) 0.88
Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull (2001) 0.88
Immunoprophylactic properties of 71-kDa cell wall-associated protein antigen of Mycobacterium tuberculosis H37Ra. Med Microbiol Immunol (1997) 0.88
Effect of acute administration of dichlorodiphenyl trichloroethane on certain enzymes of Rhesus monkey. Indian J Med Res (1978) 0.88
Cell wall and membrane changes associated with ethambutol resistance in Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother (1990) 0.88
Immunogenicity of ribonucleic acid-protein fraction of Mycobacterium tuberculosis encapsulated in liposomes. J Med Microbiol (1989) 0.87
Immunodominance of low molecular weight secretory polypeptides of Mycobacterium tuberculosis to induce cytotoxic T-lymphocyte response. Vaccine (2005) 0.87
Polymer based drug delivery systems for mycobacterial infections. Curr Drug Deliv (2004) 0.87
Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice. Clin Immunol (2007) 0.86
Liposomes and PLG microparticles as sustained release antitubercular drug carriers--an in vitro-in vivo study. Int J Antimicrob Agents (2001) 0.86
Liposomes as a carrier for mannophosphoinositide antigens of mycobacteria. Indian J Biochem Biophys (1993) 0.86
Antiarthritic activity of a standardized, multiherbal, Ayurvedic formulation containing Boswellia serrata: in vitro studies on knee cartilage from osteoarthritis patients. Phytother Res (2011) 0.86
Lipid metabolism in fungi. Crit Rev Microbiol (1984) 0.86
Replacement of acyl and alk-1-enyl groups in Clostridium butyricum phospholipids by exogenous fatty acids. Biochemistry (1975) 0.86
Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J Infect (2006) 0.85
Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta (1997) 0.85
Vaginal wall sling for anatomical incontinence and intrinsic sphincter dysfunction: efficacy and outcome analysis. J Urol (1996) 0.84
Alginate-based sustained release drug delivery systems for tuberculosis. Expert Opin Drug Deliv (2008) 0.84
When outside the norm is normal: interpreting lab data in the aged. Geriatrics (1992) 0.83
Anthrax, MEK and cancer. Cell Cycle (2002) 0.83
Effect of growth temperature on the lipid composition of Mycobacterium smegmatis ATCC 607. J Gen Microbiol (1979) 0.83
Percutaneous transseptal mitral commissurotomy in pregnant women with critical mitral stenosis. Indian Heart J (2001) 0.83
Human immune recognition-based multicomponent subunit vaccines against tuberculosis. Eur Respir J (2005) 0.83
Lipid composition and virulence of Mycobacterium tuberculosis H37Rv. Aust J Exp Biol Med Sci (1982) 0.83
Alterations in macromolecular composition and cell wall integrity by ciprofloxacin in Mycobacterium smegmatis. Lett Appl Microbiol (1999) 0.83
Antigenicity of phosphatidyl inositomannosides of Mycobacterium tuberculosis. Immunochemistry (1971) 0.83
Heliox does not improve FEV1 in acute asthma patients. J Emerg Med (1998) 0.83
Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother (2001) 0.82
Cloning, nucleotide sequence and characterization of a New Zealand rabbit metallothionein-I gene. Biochem Biophys Res Commun (1988) 0.82
Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents (2004) 0.82
A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT. Appl Radiat Isot (2009) 0.82
Sutton's aphthae and Behçet's syndrome. Indian J Dermatol (1985) 0.81
Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly (DL-lactide-co-glycolide) microparticles as carrier vehicles. FEMS Immunol Med Microbiol (1998) 0.81
Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A. FEMS Immunol Med Microbiol (1994) 0.81
Role of cyclic adenosine monophosphate in phospholipid synthesis in Mycobacterium smegmatis ATCC 607. Lipids (1995) 0.81
Ca2+/calmodulin dependent protein kinase from Mycobacterium smegmatis ATCC 607. Mol Cell Biochem (1998) 0.81
Recently described innate broad spectrum virus inhibitors. Microb Pathog (1989) 0.80
Acid phosphatase activity of promastigotes of Leishmania donovani: a marker of virulence. FEMS Microbiol Lett (1992) 0.80
Influence of lipid composition on the sensitivity of Candida albicans to antifungal agents. Indian J Biochem Biophys (1989) 0.80
On the ornithinyl ester of phosphatidylglycerol of Mycobacterium 607. J Bacteriol (1970) 0.80
Serum immunoglobulin estimation in 30 cases of cutaneous vasculitis. Indian J Dermatol Venereol Leprol (2010) 0.80
Myocardial fibrosis in the elderly. Arch Pathol Lab Med (1990) 0.80
Structures of the intradiskal loops and amino terminus of the G-protein receptor, rhodopsin. J Pept Res (2000) 0.80